LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival ...
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastases Signals of tumor agnostic benefit observed Tumor types included CRC, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback